In the REGARDS study, CRP was approved as a prognostic indicator for primary prevention for patients with a high risk of cardiovascular disease, defined as Framingham coronary risk score ≥ 10% or atherosclerotic heart disease (ASCVD) risk ≥ 7.5% [25]. Here, CRP is linked to cardiovascular disorder.